zinc finger protein 890, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ZNF890P profile across patient tissues and cancer cell-line models. ZNF890P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ZNF890P is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, ZNF890P RNA expression shows 8,939 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, LUAD, and THYM as cancer lineages where ZNF890P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF890P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF890P survival associations across molecular data types. ZNF890P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF890P RNA expression–survival associations across cancer types. High ZNF890P expression shows unfavorable associations in READ, COAD and BRCA, but favorable associations in SKCM, LUAD and ACC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for ZNF890P RNA expression.
This table summarizes ZNF890P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF890P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF890P shows lower tumor expression in THCA and higher tumor expression in LUAD, LIHC, HNSC, BRCA and COAD. The LUAD box plot shows higher ZNF890P RNA expression in tumor versus normal tissue (log2 FC = +0.107, t-test p = .001).
This table shows molecular features associated with ZNF890P in patient tissues and cancer cell lines. In patient samples, ZNF890P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
